- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer
- Interventions
- Cabozantinib + Atezolizumab
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Therapy Directory
Atezolizumab clinical trials
Directory of U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention. Browse Atezolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
512
Shown on this page
12
Current sort
Recently updated
Therapy scope
Atezolizumab
Additional filters apply within this therapy.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 13–24 of 512 matching trials for Atezolizumab.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- Gocatamig, I-DXd, Atezolizumab, Carboplatin, Etoposide, Rescue Medications
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more
- Conditions
- Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
- Interventions
- Atezolizumab, Bevacizumab, Stereotactic Beam Radiation Therapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 8
- States / cities
- La Jolla, California • Tampa, Florida • Atlanta, Georgia + 2 more
- Conditions
- Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract, Primary Adenocarcinoma of the Bladder, Primary Adenocarcinoma of the Urinary Tract, Renal Medullary Carcinoma, Squamous Cell Carcinoma of the Penis
- Interventions
- Sacituzumab govitecan, Atezolizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Endometrial Cancer
- Interventions
- Bevacizumab, Atezolizumab
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Oklahoma City, Oklahoma
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Memantine Hydrochloride, Bevacizumab, Atezolizumab
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
- Conditions
- SCLC
- Interventions
- ZL-1310, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Duarte, California • New Haven, Connecticut • Sarasota, Florida + 8 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 27
- States / cities
- Fresno, California • Glendale, California • Orange, California + 21 more
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Interventions
- BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Atezolizumab, Cabozantinib S-malate
- Biological · Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
About this Atezolizumab clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
- How to narrow results
- Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Atezolizumab.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Atezolizumab.